Halozyme Therapeutics (HALO) Non-Current Assets (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Non-Current Assets of $1.7 billion for Q1 2026, up 78.67% year-over-year from $934.5 million in Q1 2025, and down 1.79% quarter-over-quarter from $1.7 billion in Q4 2025.
Halozyme Therapeutics (HALO) Non-Current Assets (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Non-Current Assets for 17 consecutive years, with $1.7 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 78.67% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $5.2 billion (up 33.67% YoY), while the FY2025 annual figure was $1.7 billion, up 73.81% from the prior year.
- Non-Current Assets slipped to $1.7 billion in Q1 2026 per HALO's latest filing, from $1.7 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.7 billion in Q4 2025 and bottomed at $173.6 million in Q1 2022.
- Historically, Non-Current Assets has averaged $1.1 billion across 5 years, with a median of $991.1 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 4646.49% — and 2023, when it slipped 16.32%.
- Halozyme Therapeutics' Non-Current Assets stood at $1.1 billion in 2022, then declined by 10.49% to $986.8 million in 2023, then retreated by 0.88% to $978.1 million in 2024, then jumped by 73.81% to $1.7 billion in 2025, then slipped by 1.79% to $1.7 billion in 2026.
- Business Quant data shows HALO's Non-Current Assets at $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $892.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 1.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.64 Bn |
| Mar 31, 2026 | 1.67 Bn |
| Dec 31, 2025 | 1.70 Bn |
| Sep 30, 2025 | 892.48 Mn |
| Jun 30, 2025 | 931.23 Mn |
| Mar 31, 2025 | 934.50 Mn |
| Dec 31, 2024 | 978.14 Mn |
| Sep 30, 2024 | 991.05 Mn |
| Jun 30, 2024 | 981.66 Mn |
| Mar 31, 2024 | 967.94 Mn |
| Dec 31, 2023 | 986.85 Mn |
| Sep 30, 2023 | 1.01 Bn |
| Jun 30, 2023 | 1.04 Bn |
| Mar 31, 2023 | 1.08 Bn |
| Dec 31, 2022 | 1.10 Bn |
| Sep 30, 2022 | 1.21 Bn |
| Jun 30, 2022 | 1.24 Bn |
| Mar 31, 2022 | 173.56 Mn |
| Dec 31, 2021 | 178.14 Mn |
| Sep 30, 2021 | 168.12 Mn |